Zobrazeno 1 - 10
of 46
pro vyhledávání: ''
Autor:
Olivia R Court, Katherine Shemilt
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
In the RECOURSE trial which lead to its accreditation, Lonsurf (trifluridine/tipiracil) was shown to extend progression free survival (PFS) by 1.8 months in metastatic colorectal cancer. This Trust audit aims to assess the average quantity of cycles
Autor:
Joseph S. Bubalo, Kevin Behbahany
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 27(5)
Netupitant/palonestron (NEPA, Akynzeo™) is a fixed combination of netupitant 300 mg and palonosetron 0.5 mg that is indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV). NEPA is supplied as a hard gelatin capsule and indi
Autor:
Musa Baris Aykan, Halil Kizilöz, Galip Buyukturan, Gokhan Erdem, Ramazan Esen, Ramazan Acar, Yuksel Urun, Fikret Arpaci, Ismail Erturk, Birol Yildiz, Nuri Karadurmus
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 27(7)
Introduction and aim To demonstrate the real-life data about patients who underwent AHSCT due to GCT. Methods Between November 2016 and April 2020, 64 patients who received CE as high-dose chemotherapy for AHSCT in the Gulhane Education and Research
Autor:
Eric P Borrelli, Conor G. McGladrigan
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 27(4)
Background Four new agents (elotuzumab, ixazomib, panobinostat, and daratumumab) were approved by the US Food and Drug Administration (FDA) in 2015 for the treatment of multiple myeloma. Our objective was to compare the safety profiles of these new m
Autor:
Jacopo Giuliani, Andrea Bonetti
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 26(6)
The aim of this study was to assess the pharmacological costs of CDK4/6-inhibitors (palbociclib, ribociclib and abemaciclib) in hormone receptor positive (HR+)/human epidermal receptor 2-negative (HER2-) advanced or metastatic breast cancer (BC). We
Autor:
Philippe Hantson, Marine Cillis, Ludovic Gerard, Marco Gizzi, Valentine Gillion, Ismail Ould-Nana
Publikováno v:
Journal of oncology pharmacy practice, Vol. 27, no.1, p. 216-219 (2021)
Introduction Abiraterone acetate is an inhibitor of androgens biosynthesis, approved as first-line treatment in castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. Abiraterone has been rarely associated with seve
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 26(7)
Introduction Trastuzumab emtansine is an antibody-drug conjugate targeting the human epidermal growth factor receptor 2 use in recurrent metastatic breast cancer. Cases of trastuzumab emtansine-induced nodular regenerative hyperplasia are often repor
Autor:
Savas Comlek
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 26(7)
Introduction Development of hypersensitivity pneumonitis has been reported in association with combination chemotherapy consisting of gemcitabine and paclitaxel. However, diagnosis of this condition is based on computed tomography imaging and correla
Autor:
Elliyeh Ghadrdan, Samira Chaibakhsh, Sanambar Sadighi, Zahra Jahangard-Rafsanjani, Sholeh Ebrahimpour
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 26(7)
Introduction Cisplatin-associated acute kidney injury (AKI) is the major limitation to the use of cisplatin-based chemotherapy regimens. Serum creatinine as a traditional marker did not increase in a timely enough fashion in AKI patients. Therefore,
Autor:
Derya Kivrak Salim
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 25(8)
Hemangioblastomas of central nervous system are rare and indolent. Twenty-five percent of cases are in association with von Hippel–Lindau disease. Surgery is the standard therapy but un-resectable or recurrent cases need radiation or systemic thera